Geert C. Mudde
Chief Scinetific Officer, OncoQR ML GmbH, Austria
Founder & Director Swasthya Santulan Pvt.Ltd, India
Columbia University Mailman School of Public Health, USA
Ivana Haluskova Balter
French Society of Immunology, France
French Society of Immunology, France
Erasmus University Medical Centre, Netherlands
Adriana Macado Dellae Aquila
Federal University of SÃ£o Paulo Brazil
National Public Health Institute of Quebec, Canada
Recommended Global Pharmaceutical Sciences Webinars & Conferences
Euro Antibiotics 2024
- Welcome Message
- About conference
- Why to attend?
- Participation/Presentation Options
- Scientific Sessions/Tracks
- Market Analysis
- Past Conference Report
We are delighted to extend a warm welcome to you all at the Euro Antibiotic Conference, a premier gathering of experts, researchers, and professionals dedicated to advancing the field of antibiotic research and combating antimicrobial resistance.
As we come together for this significant event, our shared commitment to finding innovative solutions and driving progress in antibiotic science is truly commendable. The Euro Antibiotic Conference provides a unique platform for fostering collaboration, sharing groundbreaking discoveries, and addressing the critical challenges posed by antibiotic resistance.
Throughout the conference, you can expect an enriching experience filled with insightful keynote presentations, interactive panel discussions, and opportunities for networking with peers who share your passion for creating a healthier future. The Euro Antibiotic Conference is not just a meeting; it's a collective effort to shape the future of antibiotic research and promote global health.
Once again, welcome to the Euro Antibiotic Conference 2024. Let's embark on a journey of discovery, collaboration, and progress as we work together to address the challenges and opportunities in the ever-evolving landscape of antibiotic science.
Explore a rich tapestry of knowledge at the Euro Antibiotic Conference, where our agenda is meticulously crafted to encompass diverse facets of antibiotic and bacterial research and antimicrobial resistance. Engage with renowned keynote speakers who will share their expertise, shedding light on the latest breakthroughs, challenges, and future trajectories in the field. Dive into interactive panel discussions that delve into critical issues surrounding antibiotic development and resistance mechanisms, offering a platform for thought-provoking dialogue. Participate in hands-on workshops and breakout sessions designed to enhance your skills, complemented by a vibrant poster presentation session showcasing cutting-edge research. Our conference isn't just a gathering—it's a dynamic convergence of ideas, innovation, and collaboration, aimed at advancing the frontiers of antibiotic science.
Beyond the enriching content, the Euro Antibiotic Conference provides ample networking opportunities for professionals, researchers, and industry leaders. Forge meaningful connections during dedicated networking sessions and explore the latest innovations in our exhibition hall, where industry players showcase cutting-edge products and technologies. Social events, from welcome receptions to networking dinners, create a relaxed atmosphere for participants to connect on a personal level, fostering collaborations that extend beyond the confines of the conference. Join us for a transformative experience, where the synergy of knowledge, networking, and shared passion propels the collective mission of combating antimicrobial resistance to new heights.
Venue of the Conference: Radisson Blu Hotel Amsterdam Airport, Schiphol,
Address: Boeing Avenue 2 Amsterdam Airport Schiphol, 1119 PB Schiphol-Rijk, Netherlands
Why to attend?
Join us at the Euro Antibiotic Conference 2024 for an unparalleled opportunity to immerse yourself in the forefront of antibiotic research and antimicrobial resistance. As a participant, you'll gain access to a thoughtfully curated agenda featuring renowned keynote speakers, providing insights into the latest advancements, challenges, and future trends in the field. Engage in interactive panel discussions, workshops, and breakout sessions designed to enhance your expertise and skills, offering a unique chance to contribute to and shape the discourse surrounding antibiotic development and resistance mechanisms.
Networking lies at the heart of our conference. Connect with leading experts, professionals, and industry peers during dedicated sessions and social events. Establish valuable collaborations, exchange ideas, and explore potential partnerships that extend beyond the confines of the conference walls. The Euro Antibiotic Conference isn't just an event; it's a dynamic platform for knowledge exchange, collaboration, and forging lasting connections. Be part of this transformative experience, where your participation not only contributes to the advancement of antibiotic science but also positions you at the forefront of global efforts to combat antimicrobial resistance. Join us in shaping the future of antibiotic research and making a positive impact on global health.
Oral presentation: Oral Presentations may include the topics from researches, theoretical, professional or private practices in a concise manner. Individuals with personal experience are also welcome to present personal experiences or narratives which help others in everyday life. Speakers with a 30-minute slot should plan to speak for 20-25 minutes, and Keynote speakers should plan to speak for 40-45 minutes, with the remaining time to be used for questions and discussion by the Session Chair.
Workshop: For workshop presenters also, the topic of the talk will be the same as an Oral presentation with more specialized techniques and detailed demonstration. The generalized time duration for a workshop presentation is about 45-50 minutes. Interested participants can join with their respective team and present the workshop with their research coordinators with special group waivers on registration.
Poster presentation: Student Poster Competition will be organized at the Euro Antibiotic 2024 conference is to encourage students and recent graduates to present their original research. Presenters will be given about 5-7 minutes to present the poster including questions and answers. Judges may ask questions during the evaluation of the presentation. This is an opportunity for young scientists to learn about the recent findings of their peers to increase their capacity as multidisciplinary researchers. Poster displays will be in hard copy format of 1x1 M long.
For more details regarding Poster Presentation and Judging Criteria view Poster Presentation Guidelines.
Webinar: The webinar presentation is designed for those interested attendees who cannot join in person due to schedule conflicts or other obligations. In this option, the presenter may record the presentation and their presentation will be presented in the Webinar presentation session.
E-Poster: e-Poster is also similar to the webinar presentation. In this session, their presentation will be published in the form of a poster in the conference website and the presenter abstract will be published in the conference souvenir and journal with DOI.
Exhibition: Euro Antibiotic 2024 has the opportunity to exhibit the products and services from commercial and non-commercial organizations like Drug manufacturers, Clinical Trial Sites, Management Consultants, Chemists, Pharmacists, Business delegates and Equipment Manufacturers.
To know more about exhibitor booth details and benefits visit WHY TO EXHIBIT WITH US?
Send your queries to firstname.lastname@example.org
Advertisement: The conference program is a valuable resource that all attendees refer again and again as they navigate the conference. Advertising in the conference program is a great way to market and can help you secure long term business.
Send your proposal to email@example.com to know the available advertisement options and prices
Sponsor Euro Antibiotic 2024
Premium Sponsorship package
Additional Sponsorship package
Mail the program manager at firstname.lastname@example.org to know more about the sponsorship packages
Antibiotic discovery and development are critical in the ongoing battle against infectious diseases. Scientists employ various strategies to identify novel antibiotics, including screening natural sources, modifying existing compounds, and utilizing advanced technologies like genomics. The process involves rigorous testing for efficacy, safety, and potential resistance. Challenges such as bacterial resistance, coupled with the decline in new antibiotic approvals, highlight the urgency of innovation in this field.
Collaborative efforts between academia, pharmaceutical companies, and governmental agencies play a pivotal role in advancing research. As we face a growing threat from multidrug-resistant pathogens, investing in antibiotic development remains essential for safeguarding global health and maintaining effective tools to combat infectious diseases.
Antibiotic resistance mechanisms pose a formidable threat to global health, jeopardizing the effectiveness of our most potent medications. Bacteria develop resistance through various mechanisms, including genetic mutations and horizontal gene transfer. Mutations can lead to alterations in drug targets or the development of efflux pumps that expel antibiotics from bacterial cells. Horizontal gene transfer involves the exchange of resistance genes among bacteria, rapidly disseminating resistance within microbial communities.
Overuse and misuse of antibiotics in healthcare, agriculture, and aquaculture further accelerate resistance emergence. The intricate interplay of these mechanisms results in the creation of superbugs impervious to multiple drugs. Tackling antibiotic resistance demands a multifaceted approach, emphasizing responsible antibiotic use, surveillance, novel drug development, and global collaboration to curb the spread of resistant strains and preserve the efficacy of existing antibiotics.
Bacterial pathogenesis, the process by which bacteria cause disease, involves intricate mechanisms enabling these microorganisms to invade, colonize, and harm their host. Initial adherence to host tissues is facilitated by surface structures like pili and adhesins. Once attached, bacteria may secrete toxins that damage host cells, disrupt immune responses, or manipulate cellular functions. Some pathogens employ sophisticated strategies to evade the host's immune system, such as antigenic variation or immune mimicry.
Invasion into host cells allows bacteria to escape immune detection and exploit the host's resources for survival and replication. The host's inflammatory response can contribute to both protection and tissue damage. Understanding these complex processes is crucial for developing targeted therapies and vaccines to combat bacterial infections, addressing the ongoing challenges posed by emerging and drug-resistant bacterial pathogens in the realm of human and animal health.
Antibiotic stewardship and policy initiatives are vital components of global public health strategies aimed at mitigating antibiotic resistance. Antibiotic stewardship involves judicious and responsible use of antibiotics to preserve their efficacy and minimize resistance development. Comprehensive policies establish guidelines for healthcare practitioners, emphasizing diagnostic precision, appropriate prescription practices, and optimal treatment durations.
Public awareness campaigns also play a role in fostering responsible antibiotic use. Robust surveillance systems are implemented to monitor antibiotic consumption and resistance patterns. International collaboration is essential to address this transnational issue effectively. By promoting prudent antibiotic use, enforcing regulations, and fostering research into novel therapies, antibiotic stewardship and policy frameworks contribute to a sustainable and effective approach to safeguarding these critical medications for current and future generations.
Alternative therapies and complementary approaches offer diverse avenues for healthcare, supplementing conventional treatments and promoting holistic well-being. Practices such as acupuncture, herbal medicine, and mindfulness-based interventions have gained recognition for managing various health conditions. These approaches often focus on addressing underlying imbalances and promoting the body's natural healing mechanisms.
Integrating alternative therapies into conventional healthcare can provide personalized and patient-centered options, enhancing treatment outcomes. However, it is crucial to approach these practices with a scientific lens, emphasizing evidence-based research to validate their efficacy and safety. Collaborative efforts between traditional and alternative medicine practitioners, combined with ongoing research, can contribute to a more comprehensive and integrative healthcare system, offering patients a broader spectrum of choices for their health and wellness journey.
Clinical trials are the cornerstone of therapeutic advances, driving innovation in healthcare by rigorously evaluating new treatments, drugs, and interventions. These trials, conducted with human subjects, assess safety, efficacy, and potential side effects. Phase I trials focus on safety, Phase II on efficacy, and Phase III on large-scale confirmation of effectiveness. Breakthroughs in precision medicine, immunotherapy, and gene therapy often stem from successful trial outcomes.
Collaborations between researchers, clinicians, and pharmaceutical industries propel therapeutic advancements, addressing unmet medical needs. The evolving landscape of clinical trials embraces adaptive designs and digital technologies, expediting data collection and analysis. Ethical considerations, patient consent, and regulatory oversight ensure the integrity of these trials. Ultimately, clinical trials pave the way for transformative therapeutic discoveries, improving patient outcomes and shaping the future of medical practice.
The epidemiology of bacterial infections encompasses the study of the distribution, causes, and determinants of bacterial diseases within populations. Understanding transmission dynamics, risk factors, and patterns of infection is crucial for effective prevention and control strategies. Bacterial infections can exhibit varied epidemiological profiles, influenced by factors such as age, gender, socioeconomic status, and geographical location. Surveillance systems track the incidence and prevalence of bacterial pathogens, aiding in the identification of emerging threats and the assessment of public health interventions.
Additionally, antibiotic resistance patterns are integral to bacterial epidemiology, highlighting the importance of monitoring and addressing this global health challenge. By unraveling the complex interplay of host, pathogen, and environmental factors, epidemiological research informs evidence-based policies and interventions, contributing to the mitigation of bacterial infections and the protection of public health.
One Health is a holistic approach that recognizes the interconnectedness of human, animal, and environmental health. By acknowledging the interdependence of these domains, One Health seeks to address complex health challenges collaboratively. Shared ecosystems, zoonotic diseases, and the human-animal-environment interface underscore the need for integrated strategies. Monitoring and managing emerging infectious diseases, antibiotic resistance, and environmental degradation require interdisciplinary cooperation between healthcare professionals, veterinarians, ecologists, and policymakers.
This approach emphasizes proactive surveillance, joint research efforts, and coordinated interventions to safeguard global health. By recognizing the inextricable links between human, animal, and environmental well-being, One Health fosters resilience, enhances disease prevention, and promotes sustainable practices, reflecting a comprehensive understanding of the intricate web of factors that influence the health of our planet and its inhabitants.
Infection control and prevention are paramount in healthcare settings to mitigate the spread of infectious diseases. Rigorous protocols encompass hygiene practices, proper sanitation, and the use of personal protective equipment to reduce the risk of infections among patients and healthcare workers. Surveillance and monitoring systems track infection trends, enabling rapid response to potential outbreaks. Immunization campaigns and adherence to antimicrobial stewardship principles further contribute to infection prevention.
Education plays a crucial role in empowering healthcare personnel and the public to adopt preventive measures. In the face of emerging threats like healthcare-associated infections and antimicrobial resistance, a comprehensive and dynamic approach to infection control is essential. Robust infection control strategies not only protect individuals but also uphold public health, emphasizing the importance of a collective effort in maintaining a safe and resilient healthcare environment.
Education and public awareness play pivotal roles in promoting health, safety, and informed decision-making within communities. Comprehensive educational campaigns empower individuals to make healthier lifestyle choices, understand disease prevention measures, and recognize the importance of vaccinations. In the context of infectious diseases, such as COVID-19, public awareness campaigns disseminate accurate information, dispel myths, and encourage compliance with preventive measures like vaccination and hygiene practices. Health literacy initiatives equip people with the knowledge to navigate healthcare information effectively.
Moreover, promoting awareness about antibiotic resistance fosters responsible antibiotic use. Through targeted programs, communities can become active participants in their well-being, contributing to the overall resilience of public health systems. By fostering a culture of awareness and understanding, education becomes a powerful tool in building healthier, more informed societies.
Future trends and innovations in healthcare are poised to revolutionize the way we approach prevention, diagnosis, and treatment. Personalized medicine, leveraging genomic and molecular data, promises tailored therapies based on individual characteristics. Artificial intelligence and machine learning are advancing diagnostics, predicting disease outcomes, and streamlining drug discovery processes. Telemedicine is gaining prominence, enhancing access to healthcare services globally.
Immunotherapy and gene editing technologies show immense potential in treating previously incurable conditions. Nanotechnology is enabling targeted drug delivery, minimizing side effects. The integration of wearable devices and health apps promotes continuous monitoring and proactive health management. Furthermore, a growing emphasis on holistic approaches, such as integrative medicine, underscores the importance of addressing physical, mental, and social well-being. As technology evolves, these trends collectively shape a future healthcare landscape characterized by precision, accessibility, and a comprehensive understanding of individual and population health.
Host immune responses to bacterial infections are intricate defense mechanisms aimed at neutralizing and eliminating invading pathogens. The innate immune system acts as the first line of defense, recognizing conserved bacterial components and initiating a rapid response. Phagocytic cells engulf and digest bacteria, while other cells release antimicrobial proteins. The adaptive immune response follows, involving specialized cells like T and B lymphocytes that target specific bacterial antigens. Memory cells are then formed to confer long-term immunity. Inflammation, orchestrated by various immune cells, plays a dual role—eliminating bacteria and repairing damaged tissues.
However, bacterial pathogens have evolved strategies to evade immune detection, leading to chronic infections or recurrent diseases. Understanding the dynamics of host immune responses is crucial for developing vaccines and therapeutic interventions to enhance the body's ability to combat bacterial infections effectively.
The microbiome, comprising trillions of microorganisms in and on the human body, plays a crucial role in health, influencing digestion, immune function, and metabolic processes. Antibiotics, while essential for treating bacterial infections, can disrupt the delicate balance of the microbiome. These medications not only target pathogenic bacteria but also impact beneficial microbes, potentially leading to dysbiosis. Prolonged or frequent antibiotic use may result in long-lasting alterations to the microbiome, increasing the risk of conditions like antibiotic-associated diarrhea or Clostridium difficile infections.
Research explores the intricate relationship between antibiotics and the microbiome, aiming to develop strategies for mitigating collateral damage. Probiotics and fecal microbiota transplantation are emerging as interventions to restore microbial equilibrium post-antibiotic therapy, underscoring the importance of preserving the microbiome for overall health and well-being. Balancing effective antibiotic use with microbiome preservation represents a critical consideration in modern healthcare.
Bioinformatics and computational approaches are indispensable tools in antibiotic research, accelerating the discovery and development of novel antimicrobial agents. Analyzing vast genomic datasets, bioinformatics aids in identifying potential drug targets, predicting resistance mechanisms, and designing molecules with enhanced efficacy. Computational models simulate drug interactions, allowing for the rational design of antibiotics and optimization of existing compounds.
Additionally, metagenomics and systems biology provide insights into the microbial communities and their responses to antibiotics. Machine learning algorithms help analyze massive datasets to predict potential drug candidates and optimize treatment regimens. Integrating these technologies enhances the efficiency of antibiotic discovery, expedites drug development, and addresses the challenge of antibiotic resistance. The synergy between bioinformatics and antibiotic research underscores the potential to revolutionize our approach to combating infectious diseases and underscores the pivotal role of computational tools in shaping the future of antimicrobial development.
Pediatric antibiotic use is a critical aspect of managing infectious diseases in children. While antibiotics are essential for treating bacterial infections, their misuse contributes to antibiotic resistance. Striking a delicate balance, healthcare professionals must judiciously prescribe antibiotics, considering the child's age, weight, and the specific pathogen involved. Pediatric infectious diseases, ranging from ear infections to respiratory illnesses, necessitate tailored treatment plans. Adherence to evidence-based guidelines is paramount to ensure optimal outcomes and minimize adverse effects.
Additionally, educating parents and caregivers about the importance of completing prescribed antibiotic courses and discouraging self-medication is crucial. Ongoing research explores age-appropriate formulations and explores alternatives to minimize the impact on the developing microbiome. Responsible antibiotic stewardship in pediatric care is integral to safeguarding effective treatments for children and addressing the global challenge of antibiotic resistance.
Zoonotic bacterial infections, transmitted between animals and humans, pose significant public health concerns. These infections, often originating in wildlife or domestic animals, can result in a range of diseases, including foodborne illnesses and emerging infectious diseases. Notable examples include Salmonella, Campylobacter, and Escherichia coli. Direct contact with infected animals, consumption of contaminated food, or exposure to vectors like ticks contribute to zoonotic transmission. Rapid urbanization, agricultural practices, and climate change further amplify the risk of spillover events.
Surveillance and early detection are critical in preventing outbreaks, necessitating collaboration between veterinary and public health sectors. Holistic strategies, encompassing improved animal husbandry, strict food safety measures, and heightened public awareness, are essential to mitigate the impact of zoonotic bacterial infections, ensuring the health and well-being of both animals and humans in an interconnected global ecosystem.
Diagnostic innovations are revolutionizing the detection of bacterial infections, enhancing accuracy, speed, and efficiency. Molecular techniques, such as polymerase chain reaction (PCR), enable rapid identification of bacterial DNA, facilitating early and precise diagnosis. Next-generation sequencing technologies provide comprehensive insights into microbial genomes, aiding in the characterization of bacterial strains and their resistance profiles. Immunodiagnostics, including enzyme-linked immunosorbent assays (ELISA), detect specific bacterial antigens or antibodies, offering valuable diagnostic tools.
Microfluidic devices and biosensors enable point-of-care testing, streamlining diagnostics in resource-limited settings. Advanced imaging modalities, like magnetic resonance imaging (MRI) and positron emission tomography (PET), enhance visualization of bacterial infections within the body. Integration of artificial intelligence in data analysis further refines diagnostic accuracy. These innovations not only expedite treatment initiation but also contribute to effective antimicrobial stewardship by guiding targeted therapy, exemplifying a transformative shift towards precision diagnostics in the realm of bacterial infections.
Understanding the pharmacokinetics and pharmacodynamics of antibiotics is crucial for optimizing their efficacy and minimizing resistance development. Pharmacokinetics involves the absorption, distribution, metabolism, and excretion of antibiotics within the body. Factors such as bioavailability and drug interactions influence antibiotic concentrations at the infection site. Pharmacodynamics explores the relationship between drug concentration and microbial response, emphasizing parameters like minimum inhibitory concentration (MIC) and time above MIC.
Tailoring antibiotic regimens based on patient characteristics and the specific pathogen's susceptibility profile enhances treatment outcomes. Individualized dosing, considering factors like renal function and patient age, contributes to therapeutic success while mitigating adverse effects. The synergy between pharmacokinetic and pharmacodynamic principles guides the rational design of antibiotic therapies, promoting precision medicine in infectious disease management and bolstering the global effort to combat antibiotic resistance.
Innovations in antibiotic formulation and delivery are reshaping the landscape of infectious disease treatment. Nanotechnology has facilitated the development of nanoformulations, enhancing drug stability, bioavailability, and targeted delivery to infection sites. Liposomal and polymeric carriers improve antibiotic pharmacokinetics, reducing side effects and enhancing efficacy. Implantable devices and sustained-release formulations offer prolonged therapeutic effects, optimizing treatment adherence.
Inhalable antibiotics, such as dry powder formulations, address respiratory infections more efficiently. Combination therapies and co-formulations combat multidrug-resistant strains. Furthermore, 3D printing technology enables personalized antibiotic dosages, aligning treatment with individual patient needs. These advancements not only improve patient outcomes but also contribute to antibiotic stewardship by minimizing overuse. Embracing innovative formulation and delivery strategies holds promise in overcoming challenges associated with antibiotic efficacy and resistance, ensuring a more targeted and effective approach to infectious disease management.
Environmental factors significantly contribute to the emergence and spread of antibiotic resistance, posing a global health threat. The release of antibiotics and resistant bacteria into soil and water ecosystems, often stemming from pharmaceutical manufacturing, agriculture, and healthcare discharges, accelerates resistance development. Widespread antibiotic use in agriculture as growth promoters or for disease prevention exacerbates environmental contamination. Furthermore, suboptimal waste management practices contribute to the dissemination of resistant genes.
Environmental reservoirs serve as hubs for gene transfer among bacteria, fostering the creation of resilient strains. Climate change, altering microbial habitats and promoting the survival of resistant organisms, further complicates the scenario. Addressing antibiotic resistance mandates a comprehensive approach that integrates environmental considerations, emphasizing sustainable practices, improved waste management, and responsible antibiotic use across sectors to mitigate the impact of environmental factors on the evolution and dissemination of antibiotic resistance.
The economic impact and market dynamics of antibiotics is complex, influenced by factors such as drug development costs, market demand, and the rise of antibiotic-resistant infections. The pharmaceutical industry faces financial challenges in antibiotic research and development due to the high costs and diminishing returns compared to chronic disease medications. The market dynamics are further complicated by the need for responsible antibiotic use, potentially limiting sales volume. Antibiotic resistance escalates healthcare costs, as prolonged illnesses and increased hospitalizations become more common.
The limited duration of antibiotic treatment and lower pricing models also affect market incentives. To address these challenges, innovative funding models, market incentives, and global collaborations are essential to ensure a sustainable antibiotic market that prioritizes public health needs while maintaining economic viability for pharmaceutical companies. Balancing economic considerations with the imperative to combat antibiotic resistance is critical for the future of infectious disease management.
The market for antibiotic research and bacterial infections solutions is of paramount importance in the global healthcare landscape. This market analysis sheds light on the prevailing trends, challenges, and opportunities within the Antibiotics and Bacterial Infections conference sector. Understanding the dynamics of this market is essential for stakeholders looking to contribute to advancements in antibiotic science and combat the challenges posed by bacterial infections.
The Antibiotics and Bacterial Infections conference sector has experienced significant growth in recent years, driven by an increasing awareness of the global impact of antimicrobial resistance. With the rise of bacterial infections worldwide, the market for conferences addressing these challenges is poised for expansion. Recent market insights indicate a projected increase in the number of conferences and participants, reflecting a compound annual growth rate (CAGR) of [percentage] over the next [number] years.
Trends influencing the Antibiotics and Bacterial Infections conference sector encompass advancements in antibiotic development, discussions on novel treatment approaches, and the integration of multidisciplinary perspectives. The rise of virtual conferences, driven by technological advancements, has become a notable trend, providing a platform for wider global participation and knowledge exchange.
While the Antibiotics and Bacterial Infections conference sector faces challenges such as navigating the complexities of bacterial resistance mechanisms and the need for sustained funding, these challenges present opportunities for collaboration, research funding partnerships, and the development of innovative solutions. The growing awareness of the importance of antibiotic stewardship also provides an avenue for conferences to address evolving healthcare needs.
In conclusion, the Antibiotics and Bacterial Infections conference sector is poised for continued growth and innovation. Stakeholders in this market have the opportunity to contribute significantly to global health by addressing challenges and advancing solutions. As the demand for knowledge-sharing platforms in this field expands, conferences play a pivotal role in fostering collaboration and driving progress in antibiotic research and the fight against bacterial infections.
Past Conference Report
The Euro Antibiotic 2023 was a resounding success, bringing together leading experts, researchers, and healthcare professionals from around the world. It's held on April 11-12, 2023 in Amsterdam, Netherlands, the event served as a dynamic platform for interdisciplinary discussions, knowledge exchange, and scientific advancements in the fields of Antibiotics and Bacterial Infections.
Diverse Scientific Program
Cutting-edge Research Presentations
Expert-led Panel Discussions
The Euro Antibiotic 2023 attracted participants from over 25+ countries, emphasizing its global reach and significance. This diverse representation contributed to a rich exchange of ideas, perspectives, and experiences, enriching the overall conference experience.
Accreditation and Continuing Medical Education (CME) Credits
Social Events and Cultural Experience
We extend our heartfelt gratitude to all participants, sponsors, speakers, and organizers who contributed to the success of the Euro Antibiotic 2023. We look forward to welcoming you once again at the upcoming Euro Antibiotic 2024.
Note: The Past Conference Report provides an overview of the Euro Antibiotic 2023 held up to April 2023. For inquiries or more information, please contact us at email@example.com
Past Conference Report
All accepted abstracts will be published in respective Conference Series International Journals.
Abstracts will be provided with Digital Object Identifier by